Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri-Columbia
    • Graduate School - Theses and Dissertations (MU)
    • Theses and Dissertations (MU)
    • Dissertations (MU)
    • 2017 Dissertations (MU)
    • 2017 MU dissertations - Access restricted to MU
    • View Item
    •   MOspace Home
    • University of Missouri-Columbia
    • Graduate School - Theses and Dissertations (MU)
    • Theses and Dissertations (MU)
    • Dissertations (MU)
    • 2017 Dissertations (MU)
    • 2017 MU dissertations - Access restricted to MU
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleSubjectIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleSubjectIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    Investigation of novel therapeutic strategies for attenuating corneal fibrosis

    Fink, Michael Kurt
    View/Open
    [PDF] research.pdf (4.604Mb)
    [PDF] public.pdf (1.794Kb)
    Date
    2017
    Format
    Thesis
    Metadata
    [+] Show full item record
    Abstract
    [ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] Corneal fibrosis (scarring) is a significant cause of vision loss worldwide resulting from an exuberant wound healing response driven in part by the actions of transforming growth factor beta (TGF[beta]). Non-surgical interventions allowing for the safe and complete clinical resolution of corneal fibrosis are currently lacking in physician and veterinary ophthalmology. In order to address this significant clinical need, the research presented within this dissertation is focused on developing novel pharmacologic and gene therapies to mitigate corneal fibrosis in humans and companion animal species. This dissertation sought to evaluate the safety and efficacy of two unique pharmacologic agents (Pirfenidone and Fasudil) with known antifibrotic effects in non-ocular organ systems for attenuating TGF[beta]-mediated corneal fibrosis in vitro and in vivo. We also evaluated the ability of nanoparticle-mediated combination gene therapy (PEI-GNP) with bone morphogenetic protein 7 (BMP7) and hepatocyte growth factor (HGF) to mitigate severe corneal fibrosis in vivo following corneal alkali injury. The results of these studies demonstrated the potential clinical utility of both Pirfenidone and Fasudil (HA1077) to mitigate mild to moderate corneal fibrosis as sole antifibrotic pharmacologic agents and for combination gene therapy with BMP7+HGF to resolve moderate to severe corneal fibrosis with a single topical application of hybrid nanoparticles following corneal injury. Additional in vivo analyses are needed to evaluate potential long-term local and systemic effects owing to treatment(s) and to optimize dose and dosing regimen in a species-specific manner. Each of these therapeutic strategies holds great promise for attenuating corneal fibrosis in human and veterinary patients in clinical settings
    URI
    https://hdl.handle.net/10355/63594
    Degree
    Ph. D.
    Thesis Department
    Veterinary pathobiology (MU)
    Rights
    Access to files is limited to the University of Missouri--Columbia.
    Collections
    • 2017 MU dissertations - Access restricted to MU
    • Veterinary Pathobiology electronic theses and dissertations (MU)

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems